In ER+ cancer models, both genetic and pharmacological inhibition of FASN, hypersensitizes ERα to estrogen dependent transactivation, inducing estrogen receptor element (ERE) transcriptional activity and MAPK-ERK signaling63. The gene discussed is MAPK1; the disease is cancer.